About the API
Lurasidone is an orally administered substance that belongs to the class of atypical antipsychotic drugs (AAPD). These drugs are suggested to have less side effects in comparison to typical psychotic drugs. It is prescribed for the treatment of schizophrenia and bipolar depression ‘ specifically, for the treatment of depressive episodes associated with bipolar I disorder in adults when used alone or in combination with lithium or valproate. Lurasidone has been found to have a beneficial effect on cognitive performance in patients with acute psychosis. This suggests that lurasidone treatment may offer an approach for the prevention of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment
Lurasidone was approved by the FDA in 2010 for schizophrenia and in 2013 for depressive episodes associated with bipolar disorder. It received approval by the EMA in 2014 for schizophrenia. Lurasidone has also been launched in a number of countries outside the US and EU, including Canada, where it is approved for both indications. It is produced through a multi-step chemical process.